Prevention of myopia onset with 0.025% atropine in premyopic children.
OBJECTIVE
To evaluate the efficacy of 0.025% atropine solution for prevention of myopic shift and myopia onset in premyopic children.


METHODS
This study was designed as a retrospective cohort study. Six- to 12-year-old children with spherical equivalent refraction of <+1 diopter (D) (defined as premyopia), with cylindrical refraction of <-1 D, without amblyopia, and who received 0.025% atropine eye drops at bedtime every night or no treatment after follow-up for at least 12 months were enrolled. Fast myopic shift is defined as a myopic shift >-0.5 D per year.


RESULTS
Fifty children were enrolled in the study. Twenty-four children (average age 7.6 years old) were in the 0.025% atropine group, and 26 children (average age: 8.2 years old) were in the control group. The mean spherical refraction myopic shift in the 0.025% atropine group was -0.14 +/- 0.24 D/year, significantly lower than that in the control group, -0.58 +/- 0.34 D/year (P < 0.0001). In multiple linear regression analysis, 0.025% atropine treatment was the only independent variable in preventing myopia shift. There were statistically significant differences between the 0.025% atropine group and the control group in myopia onset and fast myopic shift (21% vs. 54%, P = 0.016; 8% vs. 58%, P = 0.0002, respectively). There was no difference between the 2 groups with regard to the symptom of photophobia (16% vs. 8%, P = 0.409). None of the children in either group complained of near-blurred vision.


CONCLUSIONS
Regular topical administration of 0.025% atropine eye drops can prevent myopia onset and myopic shift in premyopic schoolchildren for a 1-year period.
Fang
Po-Chiung
PC
Department of Ophthalmology, Chang Gung Memorial Hospital, Kaohsiung Medical Center, Chang Gung University College of Medicine, Kaohsiung County, Taiwan, Republic of China.
Chung
Mei-Yung
MY
Yu
Hun-Ju
HJ
Wu
Pei-Chang
PC
D001285:Atropine / Q000008:administration & dosage* / Q000009:adverse effects; D002648:Child; D015331:Cohort Studies; D018450:Disease Progression; D005260:Female; D006801:Humans; D008297:Male; D009184:Mydriatics / Q000008:administration & dosage / Q000009:adverse effects; D009216:Myopia / Q000188:drug therapy / Q000517:prevention & control*; D009883:Ophthalmic Solutions / Q000008:administration & dosage; D020795:Photophobia / Q000139:chemically induced; D012029:Refraction, Ocular / Q000187:drug effects; D012189:Retrospective Studies; D016896:Treatment Outcome
D009184:Mydriatics; D009883:Ophthalmic Solutions; D001285:Atropine